Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules.

[1]  H. Thabet,et al.  Synthesis of novel N-substitutedphenyl-6-oxo-3-phenylpyridazine derivatives as cyclooxygenase-2 inhibitors. , 2020, Drug development research.

[2]  Guo-Wu Rao,et al.  A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. , 2020, Current Medicinal Chemistry.

[3]  T. Takeuchi,et al.  Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain , 2020, Pharmacology research & perspectives.

[4]  S. Hanessian,et al.  Synthetic Sphingolipids with 1,2-Pyridazine Appendages Improve Antiproliferative Activity in Human Cancer Cell Lines. , 2020, ACS medicinal chemistry letters.

[5]  Yuyang Jiang,et al.  Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents , 2020 .

[6]  Huibin Zhang,et al.  Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. , 2020, European journal of medicinal chemistry.

[7]  A. M. El-Naggar,et al.  Synthesis of new oxadiazol-phthalazinone derivatives with anti-proliferative activity; molecular docking, pro-apoptotic, and enzyme inhibition profile , 2020, RSC advances.

[8]  B. Pani,et al.  Synthesis, crystal structures and biological evaluation of new pyridazine derivatives , 2020 .

[9]  Yuchuan Zhu,et al.  Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. , 2019, ACS medicinal chemistry letters.

[10]  Wei Hou,et al.  Meeting organometallic chemistry with drug discovery: CH activation enabled discovery of a new ring system of 12H-Indazolo[2,1-a]cinnolin-12-ones with anti-proliferation activity. , 2019, Bioorganic & medicinal chemistry letters.

[11]  Qihua Zhu,et al.  Discovery of Novel Dual Poly(ADP-ribose)polymerase (PARP) and Phosphoinositide 3-kinase (PI3K) Inhibitors as A Promising Strategy for Cancer Therapy. , 2019, Journal of medicinal chemistry.

[12]  A. El-Malah,et al.  New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation. , 2019, Bioorganic chemistry.

[13]  J. Klaveness,et al.  Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation , 2019, RSC advances.

[14]  Amr A. Kamel,et al.  Synthesis and vasodilator activity of some pyridazin-3(2H)-one based compounds. , 2019, Future medicinal chemistry.

[15]  N. Khalil,et al.  Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking. , 2019, Bioorganic chemistry.

[16]  Maolin Yu,et al.  Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model. , 2019, ACS medicinal chemistry letters.

[17]  C. Luo,et al.  Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors. , 2019, Journal of medicinal chemistry.

[18]  Samir CHTITA,et al.  Virtual screening in drug-likeness and structure/activity relationship of pyridazine derivatives as Anti-Alzheimer drugs , 2019, Journal of King Saud University - Science.

[19]  I. Eissa,et al.  Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR‐2 inhibitors , 2019, Archiv der Pharmazie.

[20]  Vijay T. Ahuja,et al.  Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase. , 2019, ACS medicinal chemistry letters.

[21]  J. Sangshetti,et al.  Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review. , 2019, Bioorganic & medicinal chemistry.

[22]  A. S. Youssef,et al.  Synthesis of new annulated pyridazine derivatives and studying their antioxidant and antimicrobial activities , 2019, Synthetic Communications.

[23]  M. I. Marzouk,et al.  Design, Synthesis, and Pharmacological Assay of Novel Compounds Based on Pyridazine Moiety as Potential Antitumor Agents , 2019, Journal of Heterocyclic Chemistry.

[24]  Hualiang Jiang,et al.  The Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as Novel Covalent Fibroblast Growth Factor Receptor (FGFR) Inhibitors by Rational Drug Design. , 2019, Journal of medicinal chemistry.

[25]  Yoshiyuki Kobayashi,et al.  Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators. , 2019, Bioorganic & medicinal chemistry letters.

[26]  D. Mahendiran,et al.  In vitro anti‐proliferative and in silico docking studies of heteroleptic copper(II) complexes of pyridazine‐based ligands and ciprofloxacin , 2019, Applied Organometallic Chemistry.

[27]  I. Ott,et al.  Isomeric platinum organometallics derived from pyrimidine, pyridazine or pyrazine and their potential as antitumor drugs , 2019, Inorganica Chimica Acta.

[28]  Mairi M. Littleson,et al.  Discovery of a Thiadiazole-Pyridazine Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. , 2019, Journal of medicinal chemistry.

[29]  P. Sanasi,et al.  Synthesis, characterization, and antidiabetic activity of 6‐methoxyimidazo[1,2‐ b ]pyridazine derivatives , 2019, Journal of the Chinese Chemical Society.

[30]  Samir M. El-Moghazy,et al.  Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold. , 2019, Bioorganic chemistry.

[31]  M. Indupalli,et al.  Synthesis of new analogs of 3-methyl-[1,2,4] triazolo [3,4-a] phthalazines via Suzuki coupling and evaluation of their anticancer and antimicrobial activity , 2019, Mediterranean Journal of Chemistry.

[32]  Xin Wei,et al.  Cryptolepine and aromathecin based mimics as potent G-quadruplex-binding, DNA-cleavage and anticancer agents: Design, synthesis and DNA targeting-induced apoptosis. , 2019, European journal of medicinal chemistry.

[33]  Mamta,et al.  Synthesis and bioevaluation of 6-chloropyridazin-3-yl hydrazones and 6-chloro-3-substituted-[1,2,4]triazolo[4,3-b]pyridazines as cytotoxic agents. , 2019, Bioorganic chemistry.

[34]  O. Rabal,et al.  Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. , 2019, European journal of medicinal chemistry.

[35]  H. Ashour,et al.  Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma. , 2019, Bioorganic chemistry.

[36]  Y. Shibata,et al.  Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity. , 2019, ACS medicinal chemistry letters.

[37]  Armando Varela-Ramírez,et al.  A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation , 2019, Cell Biology and Toxicology.

[38]  James Lin,et al.  Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. , 2019, ACS medicinal chemistry letters.

[39]  Tai-Lin Chen,et al.  Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1- a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links. , 2019, Journal of medicinal chemistry.

[40]  O. Çiftçi,et al.  Synthesis of New 6-[4-(2-Fluorophenylpiperazine-1-YL)]-3(2H)-Pyridazinone-2-Acethyl-2- (Substitutedbenzal)Hydrazone Derivatives and Evulation of Their Cytotoxic Effects in Liver and Colon Cancer Cell Lines , 2019, Pharmaceutical Chemistry Journal.

[41]  Wei Li,et al.  Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents. , 2019, European journal of medicinal chemistry.

[42]  Marawan Ahmed,et al.  Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities , 2019, Journal of enzyme inhibition and medicinal chemistry.

[43]  Tamer M. Ibrahim,et al.  Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition , 2019, Journal of enzyme inhibition and medicinal chemistry.

[44]  R. Danac,et al.  Synthesis, molecular modelling and anticancer evaluation of new pyrrolo[1,2-b]pyridazine and pyrrolo[2,1-a]phthalazine derivatives , 2019, Journal of enzyme inhibition and medicinal chemistry.

[45]  Xianlin Han,et al.  Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors , 2018, Journal of enzyme inhibition and medicinal chemistry.

[46]  I. Orhan,et al.  A Series of New Hydrazone Derivatives: Synthesis, Molecular Docking and Anticholinesterase Activity Studies. , 2019, Mini reviews in medicinal chemistry.

[47]  Sara Nabil,et al.  in vitro Cytotoxic Evaluation of Some New Synthesized Pyridazine Derivatives , 2019, Asian Journal of Chemistry.

[48]  Sheridan M. Hoy.  Talazoparib: First Global Approval , 2018, Drugs.

[49]  Anna Wojcicka and Anna Nowicka-Zuchowska.  Synthesis and Biological Activity of Pyridopyridazine Derivatives: A Mini Review , 2018, Mini-Reviews in Organic Chemistry.

[50]  Riham F. George,et al.  New 1-phthalazinone Scaffold based Compounds: Design, Synthesis, Cytotoxicity and Protein Kinase Inhibition Activity. , 2018, Mini-Reviews in Medical Chemistry.

[51]  R. Ben Mrid,et al.  Cytotoxicity of new pyridazin‐3(2H)‐one derivatives orchestrating oxidative stress in human triple‐negative breast cancer (MDA‐MB‐468) , 2018, Archiv der Pharmazie.

[52]  E. Van Cutsem,et al.  A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors , 2018, Clinical Cancer Research.

[53]  M. Doble,et al.  Pyridazine-based heteroleptic copper(II) complexes as potent anticancer drugs by inducing apoptosis and S-phase arrest in breast cancer cell , 2018, Inorganica Chimica Acta.

[54]  S. N. Bukhari,et al.  Novel pyrrol-2(3H)-ones and pyridazin-3(2H)-ones carrying quinoline scaffold as anti-proliferative tubulin polymerization inhibitors. , 2018, Bioorganic chemistry.

[55]  Salwa M. Soliman,et al.  Click Synthesis, Anticancer Activity and Molecular Docking Studies on Pyridazinone Scaffolds , 2018, Current organic chemistry.

[56]  Marie Evangelista,et al.  Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. , 2018, Cell metabolism.

[57]  R. Mach,et al.  Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions , 2018, ACS omega.

[58]  J. Cossy,et al.  Synthesis of α‐(Trifluoromethyl)pyridazine Derivatives , 2018 .

[59]  B. Barlaam,et al.  Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors. , 2018, ACS medicinal chemistry letters.

[60]  M. Asif.  Diverse Biologically Active Pyridazine Analogs: A Scaffold for the Highly Functionalized Heterocyclic Compounds , 2018, Review Journal of Chemistry.

[61]  Huan-Xiang Liu,et al.  Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors. , 2018, Bioorganic & medicinal chemistry.

[62]  Xiaobo Liu,et al.  Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors , 2018, Molecules.

[63]  Jeong Hee Jeon,et al.  Design and Synthesis of Novel 3-(2-Aminopyridin-3-yl)-1,2,4-Triazolo[4,3-b ]Pyridazine Derivatives as a Reversible Bruton's Tyrosine Kinase Inhibitors , 2018, Bulletin of the Korean Chemical Society.

[64]  R. Mach,et al.  Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity. , 2018, Journal of medicinal chemistry.

[65]  M. El‐Shazly,et al.  Synthesis of New Isoxazole-, Pyridazine-, Pyrimidopyrazines and Their Anti-Inflammatory and Analgesic Activity. , 2018, Medicinal chemistry (Shariqah (United Arab Emirates)).

[66]  S. Sheriff,et al.  Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors. , 2018, Bioorganic & medicinal chemistry letters.

[67]  Wagdy M. Eldehna,et al.  Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. , 2018, Bioorganic chemistry.

[68]  M. Akhter,et al.  Synthesis of Hybrids of Dihydropyrimidine and Pyridazinone as potential Anti-Breast Cancer Agents. , 2018, Mini reviews in medicinal chemistry.

[69]  M. Ansar,et al.  In Vitro Antitumor Activity of Newly Synthesized Pyridazin-3(2H)-One Derivatives via Apoptosis Induction , 2018, Pharmaceutical Chemistry Journal.

[70]  A. Abdelhamid,et al.  Induction of apoptosis by pyrazolo[3,4-d]pyridazine derivative in lung cancer cells via disruption of Bcl-2/Bax expression balance. , 2017, Bioorganic & medicinal chemistry.

[71]  刘宏民,et al.  1-苯基-4-取代酞嗪衍生物合成及抗肿瘤活性评价 , 2018 .

[72]  A. Tomkinson,et al.  Structure-activity relationships among DNA ligase inhibitors: Characterization of a selective uncompetitive DNA ligase I inhibitor. , 2017, DNA repair.

[73]  Zhong-Zhen Zhou,et al.  Design, synthesis and biological evaluation of substituted aminopyridazin-3(2H)-ones as G0/G1-phase arresting agents with apoptosis-inducing activities. , 2017, European journal of medicinal chemistry.

[74]  L. Wang,et al.  Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. , 2017, European journal of medicinal chemistry.

[75]  Mamdouh M. Ali,et al.  Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR‐2 Inhibitors , 2017, Archiv der Pharmazie.

[76]  H. Bhatt,et al.  A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. , 2017, European journal of medicinal chemistry.

[77]  M. Behalo,et al.  Synthesis of Novel Phthalazine Derivatives as Potential Anticancer and Antioxidant Agents Based on 1‐Chloro‐4‐(4‐phenoxyphenyl)phthalazine , 2017 .

[78]  S. Khanum,et al.  The anti-invasive role of novel synthesized pyridazine hydrazide appended phenoxy acetic acid against neoplastic development targeting matrix metallo proteases. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[79]  Chaewon Kim,et al.  Synthesis and Evaluation of Novel 3-Allylseleno-6-Alkylsulfonylpyridazine Derivatives with Potential Anticancer Properties , 2017 .

[80]  M. Ghoneim,et al.  Synthesis and Anticancer Studies of Novel N-benzyl Pyridazino ne Derivatives , 2017 .

[81]  Youhong Hu,et al.  Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives. , 2017, ACS medicinal chemistry letters.

[82]  Linxiao Wang,et al.  Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors. , 2017, European journal of medicinal chemistry.

[83]  Jong-Wha Jung,et al.  Recent Advances in the Synthesis of Biologically Active Cinnoline, Phthalazine and Quinoxaline Derivatives , 2017 .

[84]  P. Artursson,et al.  Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors. , 2017, Journal of medicinal chemistry.

[85]  M. Sumakanth,et al.  Synthesis, in silico and in vitro anti-proliferative studies of some novel benzamido substituted imidazo[1,2-b]pyridazin-2-ones , 2017 .

[86]  P. V. van Dam,et al.  FGFR a promising druggable target in cancer: Molecular biology and new drugs. , 2017, Critical reviews in oncology/hematology.

[87]  L. Zhang,et al.  Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors. , 2017, European journal of medicinal chemistry.

[88]  S. Zaitone,et al.  Design and Synthesis of Pyridazine Containing Compounds with Promising Anticancer Activity. , 2017, Chemical & pharmaceutical bulletin.

[89]  Tobias Karlberg,et al.  Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. , 2017, Journal of medicinal chemistry.

[90]  M. Asif.  A brief review on Triazin-pyridazinones: Synthesis and biological activities , 2017 .

[91]  K. Abouzid,et al.  Pyridazine Based Scaffolds as Privileged Structures in anti-Cancer Therapy. , 2017, Drug research.

[92]  H. Abdel‐Aziz,et al.  Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents , 2017, Journal of enzyme inhibition and medicinal chemistry.

[93]  M. Asif.  Various Chemical and Biological Activities of Pyridazinone Derivatives , 2017 .

[94]  K. Amin,et al.  Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity. , 2016, European journal of medicinal chemistry.

[95]  M. Akhter,et al.  The therapeutic journey of pyridazinone. , 2016, European journal of medicinal chemistry.

[96]  Kai Bao,et al.  Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-b] Pyridazines as Antitubulin Agents. , 2016, ACS medicinal chemistry letters.

[97]  K. S. Shashidhara,et al.  Design, synthesis, molecular docking and biological evaluation of imides, pyridazines, and imidazoles derived from itaconic anhydride for potential antioxidant and antimicrobial activities , 2016 .

[98]  K. Garber.  Cancer anabolic metabolism inhibitors move into clinic , 2016, Nature Biotechnology.

[99]  A. Saboury,et al.  Anticancer activity assessment of two novel binuclear platinum (II) complexes. , 2016, Journal of photochemistry and photobiology. B, Biology.

[100]  A. Lau,et al.  Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. , 2016, Journal of medicinal chemistry.

[101]  Lei Liang,et al.  Development of novel proteasome inhibitors based on phthalazinone scaffold. , 2016, Bioorganic & medicinal chemistry letters.

[102]  A. Gamal-Eldeen,et al.  Synthesis, cytotoxic activity, and tubulin polymerization inhibitory activity of new pyrrol-2(3H)-ones and pyridazin-3(2H)-ones. , 2016, Bioorganic chemistry.

[103]  Mamdouh M. Ali,et al.  Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives. , 2016, European journal of medicinal chemistry.

[104]  Riham F. George,et al.  Synthesis and cytotoxic activities of some pyrazoline derivatives bearing phenyl pyridazine core as new apoptosis inducers. , 2016, European journal of medicinal chemistry.

[105]  M. Doble,et al.  New pyridazine-based binuclear nickel(II), copper(II) and zinc(II) complexes as prospective anticancer agents , 2016 .

[106]  T. Kinoshita,et al.  Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors. , 2016, Bioorganic & medicinal chemistry.

[107]  K. EL-BAGHDADY,et al.  Design and Synthesis of New Phthalazinone Derivatives Containing Benzyl Moiety with Anticipated Antitumor Activity. , 2016, Biological & pharmaceutical bulletin.

[108]  Youhong Hu,et al.  Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase. , 2016, European journal of medicinal chemistry.

[109]  A. Benomar,et al.  Synthesis and antidepressant activity of 5-(benzo[b]furan-2-ylmethyl)-6-methylpyridazin-3(2H)-one derivatives , 2016, Medicinal Chemistry Research.

[110]  Adam R. Johnson,et al.  Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. , 2016, Bioorganic & medicinal chemistry letters.

[111]  K. Rangappa,et al.  Novel PARP inhibitors sensitize human leukemic cells in an endogenous PARP activity dependent manner , 2016 .

[112]  Byung Jin Byun,et al.  Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors , 2016, Archives of pharmacal research.

[113]  Salwa Elmeligie,et al.  Synthesis and Anticancer Activity of Certain Fused Pyridazine Derivatives , 2016 .

[114]  Mamdouh M. Ali,et al.  1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. , 2016, European journal of medicinal chemistry.

[115]  Jamin D Steffen,et al.  PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain. , 2015, Molecular cell.

[116]  S. Dubey,et al.  Pyridazinone: an important element of pharmacophore possessing broad spectrum of activity , 2015, Medicinal Chemistry Research.

[117]  Hong-min Liu,et al.  Spirooxindoles: Promising scaffolds for anticancer agents. , 2015, European journal of medicinal chemistry.

[118]  A. Breeze,et al.  Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. , 2014, Structure.

[119]  T. Bush,et al.  AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo , 2013 .

[120]  G. Zhao,et al.  dCTP Pyrophosphohydrase Exhibits Nucleic Accumulation in Multiple Carcinomas , 2013, European journal of histochemistry : EJH.

[121]  N. Saleem,et al.  Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia , 2013, OncoTargets and therapy.

[122]  O. Kitahara,et al.  Anti‐angiogenic and anti‐tumor effects of TAK‐593, a potent and selective inhibitor of vascular endothelial growth factor and platelet‐derived growth factor receptor tyrosine kinase , 2013, Cancer science.

[123]  R. Kurzrock,et al.  Phase I Dose-Escalation Study of Oral Selective C-Met Inhibitor Emd 1214063 in Patients with Advanced Solid Tumors , 2012 .

[124]  J. Schellens,et al.  Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[125]  C. Wermuth.  Are pyridazines privileged structures , 2011 .

[126]  A. Turck,et al.  Incorporation of pyridazine rings in the structure of functionalized π-conjugated materials , 2011 .

[127]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[128]  N. Magné,et al.  Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? , 2010, Critical reviews in oncology/hematology.

[129]  Wei-Sheng Huang,et al.  Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. , 2010, Journal of medicinal chemistry.

[130]  D. Ferraris,et al.  Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. , 2010, Journal of medicinal chemistry.

[131]  Scott B Ficarro,et al.  A structure-guided approach to creating covalent FGFR inhibitors. , 2010, Chemistry & biology.

[132]  J. Schellens,et al.  Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[133]  F. Christ,et al.  Synthesis of new pyridazine derivatives as potential anti‐HIV‐1 agents , 2009 .

[134]  L. Gediya,et al.  Promise and challenges in drug discovery and development of hybrid anticancer drugs , 2009, Expert opinion on drug discovery.

[135]  R. Kiss,et al.  7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. , 2009, Bioorganic & medicinal chemistry.

[136]  J. Low,et al.  Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology , 2007, Clinical Cancer Research.

[137]  M. Groll,et al.  20S proteasome and its inhibitors: crystallographic knowledge for drug development. , 2007, Chemical reviews.

[138]  G. Meinhardt,et al.  Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours , 2007, Expert opinion on investigational drugs.

[139]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[140]  B. Bosnich,et al.  Principles of mononucleating and binucleating ligand design. , 2004, Chemical reviews.

[141]  Anita Singh,et al.  Exploring Potential, Synthetic Methods and General Chemistry of Pyridazine and Pyridazinone: A Brief Introduction , 2003 .

[142]  D. Sun,et al.  Elevated expression of DNA ligase I in human cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.